Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 3 1

Status

Suspended 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2Genitourinary 1

Conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body 3Ovarian Neoplasms 2Melanoma 2Glioma 2Fallopian Tube Neoplasms 2Peritoneal Neoplasms 1Pancreatic Ductal Adenocarcinoma 1Neoplasm Metastasis 1Multiple Myeloma 1Limited Stage Small Cell Lung Cancer 1Glioblastoma 1Carcinoma, Renal Cell 1Carcinoma, Ovarian Epithelial 1Breast Neoplasms 1

Interventions

pembrolizumab 137Nivolumab 116Ipilimumab 68Cyclophosphamide 33Specimen Handling 31Magnetic Resonance Spectroscopy 28trametinib 23binimetinib 22fludarabine 21Interleukin-2 20dabrafenib 19relatlimab 17encorafenib 17Biopsy 17CTLA-4 Antigen 16cemiplimab 15atezolizumab 15aldesleukin 15Radiosurgery 15fludarabine phosphate 14Opdualag 14Radiotherapy 11lenvatinib 10Blood Specimen Collection 10lifileucel 9Paclitaxel 8Cisplatin 8Bevacizumab 8spartalizumab 7cobimetinib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Melanoma × Glucose × 1 year × Clear all
NCT06391099 2026-05-26

Ketogenic Dietary Intervention to Improve Response to Immunotherapy in Patients With Metastatic Melanoma and Metastatic Kidney Cancer

Ohio State University Comprehensive Cancer Center

Phase NA Suspended
60 enrolled
DermatologicGenitourinary

Carcinoma, Renal Cell, Melanoma

NCT05933577 2025-09-24

V940-001

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
1,089 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡